Akatinol Memantine tablets p / o 10mg, No. 90

• Alzheimer's type dementia, vascular dementia, mixed dementia of all severity.

Inside, during meals. The dosage regimen is set individually. It is recommended to start treatment with the appointment of the minimum effective dose.
Adults with dementia are prescribed during the 1st week of therapy at a dose of 5 mg / day, during the 2nd week - at a dose of 10 mg / day. During the 3rd week - at a dose of 15-20 mg / day. If necessary, a further weekly dose increase of 10 mg is possible until a daily dose of 30 mg is reached.
The optimal dose is achieved gradually, with increasing doses every week.

1 film-coated tablet contains
Active ingredient: memantine hydrochloride 10 mg
Excipients: lactose - 174.75 mg; microcrystalline cellulose - 52.1 mg; colloidal silicon dioxide - 1.25 mg; talc - 11.15 mg; magnesium stearate - 0.75 mg.
Sheath : methacrylic acid copolymer, type C - 1.449 mg, sodium lauryl sulfate - 0.01 mg; polysorbate 80 - 0.034 mg; triacetin - 0.15 mg; simethicone emulsion - 0.007 mg; talc - 0.35 mg.

Individual hypersensitivity to the drug, severe renal dysfunction, pregnancy, breastfeeding, children under 18 years of age (due to insufficient data).
It is prescribed with caution to patients with thyrotoxicosis, epilepsy, convulsions (including a history), with myocardial infarction, heart failure.

Tradename:

Akatinol Memantine

INN:

memantine

Dosage form:

film-coated tablets

Composition:

1 film-coated tablet contains
Active ingredient: memantine hydrochloride 10 mg
Excipients: lactose - 174.75 mg; microcrystalline cellulose - 52.1 mg; colloidal silicon dioxide - 1.25 mg; talc - 11.15 mg; magnesium stearate - 0.75 mg.
Sheath : methacrylic acid copolymer, type C - 1.449 mg, sodium lauryl sulfate - 0.01 mg; polysorbate 80 - 0.034 mg; triacetin - 0.15 mg; simethicone emulsion - 0.007 mg; talc - 0.35 mg.

Description

Film-coated tablets - tablets of white color, oblong, biconvex, with a risk on each side.

Pharmacotherapeutic group:

Remedy for dementia

ATX code : N06DX01

Pharmacological properties

Pharmacodynamics:
As a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, it has a modulating effect on the glutamatergic system. Regulates ion transport, blocks calcium channels, normalizes membrane potential, improves the transmission of nerve impulses. Improves cognitive processes, increases daily activity.

Pharmacokinetics:
After oral administration, it is rapidly and completely absorbed. The maximum concentration in blood plasma is reached within 2-6 hours. With normal renal function, no accumulation of the drug was observed. Excretion takes place in two phases. The half-life is in the first phase - 4-9 hours, in the second phase - 40-65 hours. It is excreted in the urine.

Indications for use

• Alzheimer's type dementia, vascular dementia, mixed dementia of all severity.

Contraindications

Individual hypersensitivity to the drug, severe renal dysfunction, pregnancy, breastfeeding, children under 18 years of age (due to insufficient data).
It is prescribed with caution to patients with thyrotoxicosis, epilepsy, convulsions (including a history), with myocardial infarction, heart failure.

Method of administration and dosage

Inside, during meals. The dosage regimen is set individually. It is recommended to start treatment with the appointment of the minimum effective dose.
Adults with dementia are prescribed during the 1st week of therapy at a dose of 5 mg / day, during the 2nd week - at a dose of 10 mg / day. During the 3rd week - at a dose of 15-20 mg / day. If necessary, a further weekly dose increase of 10 mg is possible until a daily dose of 30 mg is reached.
The optimal dose is achieved gradually, with increasing doses every week.

Overdose

Symptoms: increased severity of side effects.
Treatment: gastric lavage, intake of activated charcoal, symptomatic therapy.

Interaction with other medicinal products

With simultaneous use with L-dopa drugs, dopamine agonists, anticholinergics, the effect of the latter can be enhanced. When used simultaneously with barbiturates, antipsychotics, the effect of the latter may decrease. When used together, it can change (increase or decrease) the effect of dantrolene or baclofen, so the doses of drugs should be selected individually. Simultaneous administration with amantadine, ketamine and dexametophan should be avoided. An increase in plasma levels of cimetidine, procainamide, kinidine, kinin and nicotine is possible when taken concomitantly with memantine.
It is possible to reduce the level of hydrochlorothiazide while taking it with memantine.

special instructions

In patients with Alzheimer's disease at the stage of moderate to severe dementia, the ability to drive vehicles and control complex mechanisms is usually impaired. In addition, memantine can cause a change in the reaction rate, therefore, in patients receiving treatment on an outpatient basis, special care should be taken when driving or operating machinery.

Release form

Film-coated tablets, 10 mg.
10 tablets in a blister made of polyvinyl chloride film and aluminum foil. 3 or 9 blisters, together with instructions for use, are placed in a cardboard box.

Shelf life

4 years. Do not use after the expiration date.

Storage conditions

At a temperature not exceeding 25 ? C in places inaccessible to children.

Terms of dispensing from pharmacies:

On prescription.